We use cookies for a better user experience. Read our Privacy Policy

I Agree

Pulmonary Arterial Hypertension (PAH) Market

Pulmonary Arterial Hypertension (PAH) Market (Pipeline Analysis: Early-stage Drug Candidates and Late-stage Drug Candidates; and Drug Class) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Pulmonary Arterial Hypertension (PAH) Market Outlook 2028

  • The global pulmonary arterial hypertension (PAH) market was valued at US$ 5.2 Bn in 2020
  • It is estimated to expand at a CAGR of 5.4% from 2021 to 2028
  • The global pulmonary arterial hypertension (PAH) market is expected to reach the value of US$ 13.5 Bn by the end of 2028

Analysts’ Viewpoint on Pulmonary Arterial Hypertension (PAH) Market Scenario

Research and development in the drug discovery platforms and collaborative efforts of healthcare professionals & governments to introduce drugs are driving the global pulmonary arterial hypertension (PAH) market amid the coronavirus pandemic. Companies in the global pulmonary arterial hypertension (PAH) market are accelerating their product development and leveraging revenue opportunities to gain edge over competitors. Market stakeholders are extending their services arms to gain competitive edge. Market contributors in the global pulmonary arterial hypertension (PAH) market should focus on effective and cost-efficient treatments for the patients. However, lack of awareness about the treatment and detection of PAH is expected to hamper the growth of the global pulmonary arterial hypertension (PAH) market during the forecast period.

Increase in Awareness about Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a rare and progressive disorder, characterized by high blood pressure in pulmonary arteries that carry blood from the heart to the lungs. PAH occurs when pulmonary arteries become narrow in diameter or get blocked. In the past few years, there has been an increasing prevalence of PAH disorder due to rising risk factors such as HIV, sedentary lifestyle, tobacco and alcohol consumption, smoking, and other idiopathic conditions. There are high-growth opportunities for market players in the near future due to increasing prevalence of PAH across the globe.

Various treatments are available in the market that helps in controlling and slowing down the growth of the diseases and improving the quality of life. In addition, the approval of few effective drugs and the occurrence of favorable pipeline are some of primary factors that drive the global market. Moreover, favorable policies by government has contributed in boosting the demand in the global pulmonary arterial hypertension market.

To know the scope of our report Get a Sample on Pulmonary Arterial Hypertension (PAH) Market

Rapid Growth in Geriatric Population to Fuel Market Expansion

The increase in geriatric population in developing countries is expected to drive the global pulmonary arterial hypertension market in the upcoming years. The rising incidence of PAH in the geriatric population is driving the global pulmonary arterial hypertension market during the forecast period. Aging is one of the non-modifiable factors that increases the risk related to PAH. Elderly people are more susceptible to this disease due to diastolic dysfunction and age-associated blood vessel stiffening. Several educational programs have been initiated by key market contributors and governments to increase awareness about PAH among healthcare providers and patients. All these factors are expected to boost the global pulmonary arterial hypertension market over the next few years.

Get a glimpse of the in-depth analysis through our Report Brochure

Technological Advancements and Approval of New Drugs to Drive Global Market

Technological advancements in drug discovery & development, along with rising research & development activities across the globe are driving the pulmonary arterial hypertension (PAH) market. Based on drug class, the global pulmonary arterial hypertension (PAH) market has been classified into prostacyclin & prostacyclin analogs, PDE-5 inhibitors, ERAs (endothelin receptor antagonists), and soluble guanylate cyclase (sGC) stimulators. The prostacyclin & prostacyclin analogs segment is expected to dominate the market in the near future due to high demand. The SGC simulators segment is anticipated to grow at a rapid pace during the forecast period. sGC stimulators can ensure maximum activation of sGC by potentiating NO-sGC signaling. Riociguat (Adempas from Bayer) is the only drug approved for PAH in this category.

Expanding operations in future? To get the perfect launch ask for a custom report

Promising Drug Pipeline to Boost Market in North America

Geographically, North America is projected to dominate the global pulmonary arterial hypertension (PAH) market during the forecast period. North America is followed by Europe, and the market in both regions is projected to grow remarkably throughout the forecast period. This can be ascribed to the availability of commercialization of new PAH drugs coupled with a promising drug pipeline. In addition, growing awareness among people in both regions about the rising availability of treatment for pulmonary arterial hypertension is also pushing the market growth.

Moreover, Asia Pacific possess lucrative opportunities for the market players. Countries such as Japan, New Zealand, Australia, China, and India are projected to offer high growth opportunities attributing to growing penetration of global players.

Pulmonary Arterial Hypertension (PAH) Market: Overview

  • According to Transparency Market Research’s latest report on the global pulmonary arterial hypertension (PAH) market for the historical period 2017–2019 and forecast period 2021–2028, increase in initiatives by key players, higher cases of pulmonary arterial hypertension, rise in adoption rate, availability of reimbursement, and entry of generics are projected to drive the global market during the forecast period.

Increase in Collaborations for Development of Novel Products: Key Driver

  • Focus on collaborations & mergers by leading players to develop innovative products is anticipated to boost the growth of the global market during the forecast period. In 2017, Bayer AG and Vectura Group plc extended their collaboration to develop an upgraded version of nebulizer Breelib that improves the efficacy of iloprost aerosol therapy for pulmonary atrial hypertension. According to the National Institutes of Health, the nebulizer is still in clinical trial and the study was finished in March 2020.
  • In September 2018, United Therapeutics entered into a collaboration with MannKind Corporation for the development and commercialization of dry powder formulation of treprostinil. This research was conducted by Mannkind on behalf of United Therapeutics for products outside the scope of the licensing and collaboration agreement.

COVID-19 Impact Analysis

  • The impact of the coronavirus outbreak on the industry peaked during early 2020, wherein pulmonary arterial hypertension patients were at a higher risk of suffering from coronavirus crisis
  • Other challenges including hindrance in diagnostic testing, changed guidelines pertaining to the hospital & emergency care, and interrupted drug supply chain had impeded the industry expansion
  • The pandemic has reinforced the importance of pulmonary arterial hypertension drugs as a response to the increasing number of hospitalized PAH-COVID-19 patients.

Side Effects Associated with PAH Drugs: Key Restraint

  • Side effects associated with PAH drugs are likely to hamper the growth of the global market. Vasodilators are primarily prescribed for the treatment of patients with PAH to open blocked and narrowed blood vessels.
  • According to studies, vasodilators have a number of side effects including edema, heart palpitations, tachycardia, and chest pain. Due to the substantial side effects associated with the use of vasodilators among chronically ill patients, the U.S. FDA regulates the use of this drug.
  • Moreover, manufacturers of PAH drugs that treat high blood pressure and dilate blood vessels are required to submit reasonable assurance regarding the safety and effectiveness of the drugs. These drugs require the U.S. FDA approval before commercialization.
  • The FDA drug approval represents a complicated process that demonstrates the safety and efficacy of the drug. Hence, a time-consuming regulatory process and side effects related to the usage of PAH drugs are projected to restrain the global market during the forecast period.

Pulmonary Arterial Hypertension (PAH) Market: Competition Landscape

  • This report profiles major players in the global pulmonary arterial hypertension (PAH) market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global pulmonary arterial hypertension (PAH) market is highly fragmented, with the presence of a number of international as well as regional players
  • Leading players operating in the global pulmonary arterial hypertension (PAH) market are
    • Actelion Pharmaceuticals, Ltd.
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc
    • Pfizer, Inc.
    • United Therapeutics Corporation, among others

Pulmonary Arterial Hypertension (PAH) Market: Key Developments

  • Key players in the global pulmonary arterial hypertension (PAH) market are improving their market position by adopting various strategies such as mergers & acquisitions and research collaborations with other companies to launch innovative products and consolidate their market positions across the world. A few expansion strategies adopted by players operating in the global pulmonary arterial hypertension (PAH) market are:
    • In November 2020, Mylan N.V. merged with Pfizer, Inc.’s Upjohn Business to form Viatris, Inc. Viatris provides a robust portfolio of biosimilars, branded & complex generics, and over-the-counter products, including the PAH drug Revatio
    • In July 2021, Uptravi, belonging to Prostacyclin and Prostacyclin Analogs segment, received the FDA approval for intravenous use in pulmonary arterial hypertension patients
    • The report on the global pulmonary arterial hypertension (PAH) market discusses individual strategies, followed by company profiles of manufacturers of pulmonary arterial hypertension (PAH) market products
  • The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global pulmonary arterial hypertension (PAH) market

Pulmonary Arterial Hypertension (PAH) Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 5.2 Bn

Market Forecast Value in 2028

US$ 13.5 Bn

Growth Rate (CAGR)

5.4%

Forecast Period

2021–2028

Quantitative Units

US$ Bn for Value

Market Analysis

It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market player - competition matrix (by tier and size of companies)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Drug Class
    • Prostacyclin & Prostacyclin Analogs
    • Endothelin Receptor Antagonists (ERAs)
    • Phosphodiesterase-5 (PDE-5) Inhibitors
    • Soluble Guanylate Cyclase (sGC) Stimulators
  • Pipeline Analysis
    • Early-stage Drug Candidates (Phase I & Phase II)
    • Late-stage Drug Candidates (Phase III & Registration Phase)

Regions Covered

  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Actelion Pharmaceuticals Ltd.
  • Gilead Sciences Inc.
  • Pfizer, Inc.
  • GlaxoSmithKline plc
  • Novartis International AG
  • Bayer HealthCare
  • United Therapeutics Corp
  • Other prominent players

Customization Scope

Available upon request

Pricing

Available upon request

Pulmonary Arterial Hypertension (PAH) Market – Segmentation

Pipeline Analysis
  • Early-stage Drug Candidates (Phase I & Phase II)
  • Late-stage Drug Candidates (Phase III & Registration Phase)
Drug Class
  • Prostacyclin and Prostacyclin Analogs
  • Endothelin Receptor Antagonists (ERAs)
  • Phosphodiesterase-5 (PDE-5) Inhibitors
  • Soluble Guanylate Cyclase (sGC) Stimulators
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Pulmonary Arterial Hypertension (PAH) Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of pulmonary arterial hypertension (PAH) market?

Pulmonary arterial hypertension (PAH) market is expected to reach the value of US$ 13.5 Bn by the end of 2028

What is the anticipated CAGR of the pulmonary arterial hypertension (PAH) market in the forecast period?

Pulmonary arterial hypertension (PAH) market is estimated to expand at a CAGR of 5.4% from 2021 to 2028

What are the key driving factors for the growth of the pulmonary arterial hypertension (PAH) market?

Pulmonary arterial hypertension (PAH) market is driven by increase in geriatric population in developing countries and rising incidence of PAH in the geriatric population

Which region is expected to project the highest market share in the global pulmonary arterial hypertension (PAH) market?

North America accounted for a major share of the global pulmonary arterial hypertension (PAH) market during the forecast period

Who are the key players in the global pulmonary arterial hypertension (PAH) market?

Key players in the global market include Actelion Pharmaceuticals, Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Pfizer, Inc., and United Therapeutics Corporation

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Pulmonary Arterial Hypertension (PAH) Market

4. Market Overview

    4.1. Introduction

        4.1.1. Drug Class Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast, 2017–2028

5. Key Insights

    5.1. Healthcare Industry Overview

    5.2. Top 3 players operating in the market space

    5.3. Technological Advancements

    5.4. Key Mergers & Acquisitions

    5.5. Disease Prevalence & Incidence Rate globally with key countries

    5.6. COVID-19 Pandemics Impact on Industry (value chain and short / mid / long term impact)

6. Global Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast, by Drug Class

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Drug Class, 2017–2028

        6.3.1. Prostacyclin & Prostacyclin Analogs

        6.3.2. Endothelin Receptor Antagonists (ERAs)

        6.3.3. Phosphodiesterase-5 (PDE-5) Inhibitors

        6.3.4. Soluble Guanylate Cyclase (sGC) Stimulators

    6.4. Market Attractiveness Analysis, by Drug Class

7. Global Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast, by Pipeline Analysis

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Pipeline Analysis, 2017–2028

        7.3.1. Early-stage Drug Candidates (Phase I & Phase II)

        7.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)

    7.4. Market Attractiveness Analysis, by Pipeline Analysis

8. Global Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Market Value Forecast, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. Market Attractiveness Analysis, by Country/Region

9. North America Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast, by Drug Class, 2017–2028

        9.2.1. Prostacyclin & Prostacyclin Analogs

        9.2.2. Endothelin Receptor Antagonists (ERAs)

        9.2.3. Phosphodiesterase-5 (PDE-5) Inhibitors

        9.2.4. Soluble Guanylate Cyclase (sGC) Stimulators

    9.3. Market Value Forecast, by Pipeline Analysis, 2017–2028

        9.3.1. Early-stage Drug Candidates (Phase I & Phase II)

        9.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)

    9.4. Market Value Forecast, by Country, 2017–2028

        9.4.1. U.S.

        9.4.2. Canada

    9.5. Market Attractiveness Analysis

        9.5.1. By Drug Class

        9.5.2. By Pipeline Analysis

        9.5.3. By Country

10. Europe Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Drug Class, 2017–2028

        10.2.1. Prostacyclin & Prostacyclin Analogs

        10.2.2. Endothelin Receptor Antagonists (ERAs)

        10.2.3. Phosphodiesterase-5 (PDE-5) Inhibitors

        10.2.4. Soluble Guanylate Cyclase (sGC) Stimulators

    10.3. Market Value Forecast, by Pipeline Analysis, 2017–2028

        10.3.1. Early-stage Drug Candidates (Phase I & Phase II)

        10.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)

    10.4. Market Value Forecast, by Country/Sub-region, 2017–2028

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

    10.5. Market Attractiveness Analysis

        10.5.1. By Drug Class

        10.5.2. By Pipeline Analysis

        10.5.3. By Country/Sub-region

11. Asia Pacific Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Drug Class, 2017–2028

        11.2.1. Prostacyclin & Prostacyclin Analogs

        11.2.2. Endothelin Receptor Antagonists (ERAs)

        11.2.3. Phosphodiesterase-5 (PDE-5) Inhibitors

        11.2.4. Soluble Guanylate Cyclase (sGC) Stimulators

    11.3. Market Value Forecast, by Pipeline Analysis, 2017–2028

        11.3.1. Early-stage Drug Candidates (Phase I & Phase II)

        11.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)

    11.4. Market Value Forecast, by Country/Sub-region, 2017–2028

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Market Attractiveness Analysis

        11.5.1. By Drug Class

        11.5.2. By Pipeline Analysis

        11.5.3. By Country/Sub-region

12. Latin America Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug Class, 2017–2028

        12.2.1. Prostacyclin & Prostacyclin Analogs

        12.2.2. Endothelin Receptor Antagonists (ERAs)

        12.2.3. Phosphodiesterase-5 (PDE-5) Inhibitors

        12.2.4. Soluble Guanylate Cyclase (sGC) Stimulators

    12.3. Market Value Forecast, by Pipeline Analysis, 2017–2028

        12.3.1. Early-stage Drug Candidates (Phase I & Phase II)

        12.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)

    12.4. Market Value Forecast, by Country/Sub-region, 2017–2028

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Market Attractiveness Analysis

        12.5.1. By Drug Class

        12.5.2. By Pipeline Analysis

        12.5.3. By Country/Sub-region

13. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Drug Class, 2017–2028

        13.2.1. Prostacyclin & Prostacyclin Analogs

        13.2.2. Endothelin Receptor Antagonists (ERAs)

        13.2.3. Phosphodiesterase-5 (PDE-5) Inhibitors

        13.2.4. Soluble Guanylate Cyclase (sGC) Stimulators

    13.3. Market Value Forecast, by Pipeline Analysis, 2017–2028

        13.3.1. Early-stage Drug Candidates (Phase I & Phase II)

        13.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)

    13.4. Market Value Forecast, by Country/Sub-region, 2017–2028

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Market Attractiveness Analysis

        13.5.1. By Drug Class

        13.5.2. By Pipeline Analysis

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player - Competition Matrix (by tier and size of companies)

    14.2. Market Share Analysis, by Company, 2020

    14.3. Company Profiles

        14.3.1. Actelion Pharmaceuticals Ltd.

            14.3.1.1. Company Overview (HQ, Business Segments, Employee)

            14.3.1.2. Product Portfolio

            14.3.1.3. SWOT Analysis

            14.3.1.4. Strategic Overview

        14.3.2. Gilead Sciences, Inc.

            14.3.2.1. Company Overview (HQ, Business Segments, Employee)

            14.3.2.2. Product Portfolio

            14.3.2.3. SWOT Analysis

            14.3.2.4. Strategic Overview

        14.3.3. Pfizer, Inc.

            14.3.3.1. Company Overview (HQ, Business Segments, Employee)

            14.3.3.2. Product Portfolio

            14.3.3.3. SWOT Analysis

            14.3.3.4. Strategic Overview

        14.3.4. GlaxoSmithKline plc

            14.3.4.1. Company Overview (HQ, Business Segments, Employee)

            14.3.4.2. Product Portfolio

            14.3.4.3. SWOT Analysis

            14.3.4.4. Strategic Overview

        14.3.5. United Therapeutics Corp

            14.3.5.1. Company Overview (HQ, Business Segments, Employee)

            14.3.5.2. Product Portfolio

            14.3.5.3. SWOT Analysis

            14.3.5.4. Strategic Overview

        14.3.6. Novartis International AG

            14.3.6.1. Company Overview (HQ, Business Segments, Employee)

            14.3.6.2. Product Portfolio

            14.3.6.3. SWOT Analysis

            14.3.6.4. Strategic Overview

        14.3.7. Bayer HealthCare

            14.3.7.1. Company Overview (HQ, Business Segments, Employee)

            14.3.7.2. Product Portfolio

            14.3.7.3. SWOT Analysis

            14.3.7.4. Strategic Overview

        14.3.8. Other prominent players

            14.3.8.1. Company Overview (HQ, Business Segments, Employee)

            14.3.8.2. Product Portfolio

            14.3.8.3. SWOT Analysis

            14.3.8.4. Strategic Overview

List of Tables

Table 1: List of Abbreviations

Table 2: Market Snapshot: Global Pulmonary Arterial Hypertension Market (2017 & 2020)

Table 3: Annual Treatment Cost with Various PAH Drugs in the U.S.

Table 4: Event Impact Analysis: Global PAH Market

Table 5: Global Pulmonary Arterial Hypertension Market Revenue (US$ Mn), by Drug Class, 2017-2028

Table 6: Historical Sales Data: Prostacyclin & Prostacyclin Analog Brands

Table 7: Historical Sales Data: Endothelin Receptor Antagonist Brands

Table 8: Historical Sales Data: Phosphodiesterase 5 Inhibitor Brands

Table 9: Pulmonary Arterial Hypertension: Phase I & Phase II Molecules

Table 10: Global Pulmonary Arterial Hypertension Market Revenue (US$ Mn), by Geography, 2017-2028 

Table 11: List of Major Countries in North America

Table 12: List of Major Countries in Europe

Table 13: List of Major Countries in Asia Pacific

Table 14: List of Major Countries in Latin America

Table 15: List of Major Countries in Middle East & Africa

List of Figures

Figure 1: Pulmonary Arterial Hypertension (PAH): Market Segmentation

Figure 2: Global Pulmonary Arterial Hypertension Market (US$ Mn), by Drug Class, 2019

Figure 3: Comparative Analysis: Global Pulmonary Arterial Hypertension Market Revenue (Value %), by Region, 2020 & 2028

Figure 4: Global Pulmonary Arterial Hypertension Market Share Analysis (Value %), by Key Players, 2020

Figure 5: Comparative Analysis: Global Pulmonary Arterial Hypertension Market Revenue, by Drug Class, 2020 & 2028 (Value %)

Figure 6: Global Prostacyclin & Prostacyclin Analogs Market Revenue (US$ Mn), 2017-2028

Figure 7: Global Endothelin Receptor Antagonists Market Revenue (US$ Mn), 2017-2028

Figure 8: Global Phosphodiesterase 5 Inhibitors Market Revenue (US$ Mn), 2017-2028

Figure 9: Global Soluble Guanylate Cyclase Stimulators Market Revenue (US$ Mn), 2017 – 2020

Figure 10: Major Steps: Drug Development and Commercialization

Figure 11: Global Uptravi (selexipag) Market Revenue (US$ Mn), 2017 – 2020

Figure 12: North America Pulmonary Arterial Hypertension Market Revenue (US$ Mn), 2017-2028

Figure 13: Europe Pulmonary Arterial Hypertension Market Revenue (US$ Mn), 2017-2028

Figure 14: Asia Pacific Pulmonary Arterial Hypertension Market Revenue (US$ Mn), 2017-2028

Figure 15: Latin America Pulmonary Arterial Hypertension Market Revenue (US$ Mn), 2017-2028

Figure 16: Middle East & Africa Pulmonary Arterial Hypertension Market Revenue (US$ Mn), 2017-2028

Figure 17: Actelion Pharmaceuticals, Ltd.: Annual Revenue (US$ Mn), 2017-2028

Figure 18: Bayer HealthCare: Annual Revenue (US$ Mn), 2017-2028

Figure 19: Gilead Sciences, Inc.: Annual Revenue (US$ Mn), 2017-2028

Figure 20: GlaxoSmithKline plc: Annual Revenue (US$ Mn), 2017-2028

Figure 21: Novartis International AG: Annual Revenue (US$ Mn), 2017-2028

Figure 22: Pfizer, Inc.: Annual Revenue (US$ Mn), 2017-2028

Figure 23: United Therapeutics Corporation: Annual Revenue (US$ Mn), 2017-2028

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

948

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved